Suppr超能文献

[老年糖尿病]

[Diabetes mellitus in old age].

作者信息

Zeyfang Andrej, Zeeh Joachim, Bahrmann Anke, Kugler Janine N, Heppner Hans Jürgen

机构信息

Klinik für Innere Medizin, Altersmedizin, Diabetologie und Palliativmedizin, medius KLINIK OSTFILDERN-RUIT, Hedelfinger Str. 166, 73760, Ostfildern, Deutschland.

Institut für Epidemiologie, Universität Ulm, Albert-Einstein-Allee 41, 89081, Ulm, Deutschland.

出版信息

Z Gerontol Geriatr. 2021 Feb;54(1):61-71. doi: 10.1007/s00391-020-01815-1. Epub 2020 Nov 26.

Abstract

In the treatment of diabetes in old age cognitive, functional and constitutional resources of the individual must be taken into account. Purely glycated hemoglobin (HbA1c)-oriented treatment goals are less relevant. The primary focus should be freedom from symptoms while avoiding hypoglycemia and maintaining the quality of life. The geriatric assessment helps to clarify the current functional, psychological and cognitive status as well as the need for support in multimorbid older people and to define appropriate treatment strategies. With drug treatment of diabetes in old age, particular attention must be paid to renal insufficiency and dehydration as well as slow dose adjustments. According to the Robert Koch Institute (RKI), diabetes patients belong to the risk group for a severe course of the coronavirus disease 2019 (COVID-19); further risk factors are high blood pressure, underlying oncological diseases, cerebrovascular and coronary heart diseases.

摘要

在老年糖尿病治疗中,必须考虑个体的认知、功能和体质状况。单纯以糖化血红蛋白(HbA1c)为导向的治疗目标相关性较低。主要重点应是无糖尿病症状,同时避免低血糖并维持生活质量。老年综合评估有助于明确多病共存的老年人当前的功能、心理和认知状况以及支持需求,并确定合适的治疗策略。在老年糖尿病药物治疗中,必须特别注意肾功能不全、脱水以及缓慢的剂量调整。根据德国罗伯特·科赫研究所(RKI)的数据,糖尿病患者属于2019冠状病毒病(COVID-19)重症病程的风险群体;其他风险因素包括高血压、潜在肿瘤疾病、脑血管疾病和冠心病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/812f/7689191/f8293b01376f/391_2020_1815_Fig1_HTML.jpg

相似文献

1
[Diabetes mellitus in old age].
Z Gerontol Geriatr. 2021 Feb;54(1):61-71. doi: 10.1007/s00391-020-01815-1. Epub 2020 Nov 26.
2
[Diabetes in old age: HbA1c - and then what?].
Dtsch Med Wochenschr. 2015 Jun;140(12):879-81. doi: 10.1055/s-0041-102451. Epub 2015 Jun 12.
3
Glycemic control predicts SARS-CoV-2 prognosis in diabetic subjects.
Acta Diabetol. 2023 Jun;60(6):817-825. doi: 10.1007/s00592-023-02073-4. Epub 2023 Mar 20.
8
[HEMOGLOBIN A1C AND MORTALITY FROM COVID-19].
Harefuah. 2021 Oct;160(10):645-650.
9
Haemoglobin A1c is a predictor of COVID-19 severity in patients with diabetes.
Diabetes Metab Res Rev. 2021 Jul;37(5):e3398. doi: 10.1002/dmrr.3398. Epub 2020 Sep 23.
10
Hypoglycemia at the time of Covid-19 pandemic.
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1143-1146. doi: 10.1016/j.dsx.2020.07.003. Epub 2020 Jul 10.

本文引用的文献

1
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
2
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
PLoS Med. 2019 Dec 9;16(12):e1002983. doi: 10.1371/journal.pmed.1002983. eCollection 2019 Dec.
3
Intensive Glucose Control and Type 2 Diabetes - 15 Years On. Reply.
N Engl J Med. 2019 Sep 26;381(13):1293. doi: 10.1056/NEJMc1909041.
4
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
5
Heart-Failure Therapy - New Drugs but Old Habits?
N Engl J Med. 2019 Nov 21;381(21):2063-2064. doi: 10.1056/NEJMe1912180. Epub 2019 Sep 19.
6
SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
Cell Metab. 2019 Oct 1;30(4):609-613. doi: 10.1016/j.cmet.2019.08.015. Epub 2019 Aug 30.
7
[Journal Club].
Z Gerontol Geriatr. 2019 Jul;52(4):391-392. doi: 10.1007/s00391-019-01565-9.
8
Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus.
J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):721-733. doi: 10.1002/jcsm.12432. Epub 2019 Apr 23.
10
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Circ Res. 2018 May 11;122(10):1439-1459. doi: 10.1161/CIRCRESAHA.117.311588.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验